Results 231 to 240 of about 381,513 (352)

Surgical Outcomes and Recurrence Management in Borderline Resectable Hepatocellular Carcinoma: Implications for Multidisciplinary Strategies

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Multivariate analysis identified that up‐to‐7 out (p < 0.001), lymph node metastasis (p < 0.001), and non‐anatomical resection (p = 0.02) were independent predictors of cancer recurrence, while older age (p = 0.01), Child‐Pugh B (p < 0.001), up‐to‐7 out (p = 0.01), macrovascular invasion (p = 0.01), and lymph node metastasis (p < 0.001) were ...
Koichiro Haruki   +9 more
wiley   +1 more source

Artificial Intelligence for Bone: Theory, Methods, and Applications

open access: yesAdvanced Intelligent Discovery, EarlyView.
Advances in artificial intelligence (AI) offer the potential to improve bone research. The current review explores the contributions of AI to pathological study, biomarker discovery, drug design, and clinical diagnosis and prognosis of bone diseases. We envision that AI‐driven methodologies will enable identifying novel targets for drugs discovery. The
Dongfeng Yuan   +3 more
wiley   +1 more source

Solitary fibrous tumor with bone metastasis: case report. [PDF]

open access: yesJ Surg Case Rep
Zhou-Chau KA   +2 more
europepmc   +1 more source

Extramedullary Disease—Achilles Heel in Myeloma?

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar   +7 more
wiley   +1 more source

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy